
==== Front
Curr Cardiol Rep
Curr Cardiol Rep
Current Cardiology Reports
1523-3782
1534-3170
Springer US New York

39110386
2096
10.1007/s11886-024-02096-5
Heart Failure (HJ Eisen, Section Editor)
Precision Genetic Therapies: Balancing Risk and Benefit in Patients with Heart Failure
Johnston Jamie R. 1
Adler Eric D. eradler@health.ucsd.edu

2
1 https://ror.org/05g3dte14 grid.255986.5 0000 0004 0472 0419 Department of Biomedical Sciences, College of Medicine, Florida State University, Tallahassee, FL 32306 USA
2 https://ror.org/0168r3w48 grid.266100.3 0000 0001 2107 4242 Division of Cardiology, Department of Internal Medicine, University of California San Diego, La Jolla, CA 92037 USA
7 8 2024
7 8 2024
2024
26 9 973983
2 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Purpose of Review

Precision genetic medicine is evolving at a rapid pace and bears significant implications for clinical cardiology. Herein, we discuss the latest advancements and emerging strategies in gene therapy for cardiomyopathy and heart failure.

Recent Findings

Elucidating the genetic architecture of heart failure has paved the way for precision therapies in cardiovascular medicine. Recent preclinical studies and early-phase clinical trials have demonstrated encouraging results that support the development of gene therapies for heart failure arising from a variety of etiologies. In addition to the discovery of new therapeutic targets, innovative delivery platforms are being leveraged to improve the safety and efficacy of cardiac gene therapies.

Summary

Precision genetic therapy represents a potentially safe and effective approach for improving outcomes in patients with heart failure. It holds promise for radically transforming the treatment paradigm for heart failure by directly targeting the underlying etiology. As this new generation of cardiovascular medicines progress to the clinic, it is especially important to carefully evaluate the benefits and risks for patients.

Keywords

Heart Failure
Cardiomyopathy
Muscular Dystrophy
Gene Therapy
Gene Editing
Gene Transfer
http://dx.doi.org/10.13039/100000002 National Institutes of Health R01HL155281 Adler Eric D. http://dx.doi.org/10.13039/100000900 California Institute for Regenerative Medicine issue-copyright-statement© Springer Science+Business Media, LLC, part of Springer Nature 2024
==== Body
pmcIntroduction

Heart failure (HF) is a global pandemic that remains a formidable challenge in modern cardiovascular medicine. It is estimated that HF affects at least approximately 64 million people across the globe [1]. While the incidence of HF appears to have stabilized, the prevalence is on the rise because of an aging population in addition to increased availability and use of evidence-based treatments that are prolonging patient survival [2]. While these interventions have increased survival and quality of life in subsets of patients, HF continues to represent a substantial social and economic burden. Gene therapy, defined as the use of genetic material for clinical applications to prevent, treat, or cure human disease, has emerged as a promising strategy to combat this complex clinical syndrome [3]. In contrast to cotemporary therapeutic modalities for HF, gene therapy has the potential to reshape the treatment paradigm by directly targeting the underlying etiology [4].

In this Review article, we summarize recent progress in the field and innovative strategies on the horizon in gene therapy for HF. We begin by describing the key categories of gene therapy, including gene transfer, genome editing, and epigenome editing, along with their respective mechanisms. For recent advances on the rapidly expanding application of RNA interference in cardiovascular precision medicine, we refer the readers to the following excellent review articles [5–7]. We then outline the various gene therapy delivery modalities, including viral and non-viral-mediated approaches. We conclude by discussing the application of gene therapy in the context of rare and common determinants of HF, with a focus on muscular dystrophies and inherited cardiomyopathies. As many of these potential therapies are at preclinical and clinical stages of development, we place particular emphasis on the risks and benefits of these next generation cardiovascular precision medicines.

Gene Transfer

Gene transfer, otherwise referred to as gene replacement, seeks to deliver a functional copy of a gene to cells or tissues of interest. This is accomplished by designing a viral construct containing the coding sequence for the gene of interest (GOI) and cis-regulatory elements (i.e., gene promoters, enhancers, silencers, microRNA cassettes). Although plasmids can also be used to deliver transgenes, there has been little success with this method for in vivo cardiovascular applications. Selecting the appropriate cis-regulatory elements is critical for restricting transgene expression in the tissue(s) of interest, ensuring that expression levels are optimal for therapeutic efficacy, and for reducing potential cellular toxicity associated with transgene overexpression. Commonly used transgene promoters for muscle gene therapy include desmin (DES), myosin light chain (MLC2v), skeletal muscle alpha actin-based (HSA), muscle creatine kinase and/or myosin heavy chain-based (CK6, CK8, MHCK7), cardiac troponin T (TNNT2), ubiquitous promoters (CMV, CAG), and synthetic derivatives [8]. The length of the GOI is another relevant consideration owing to the size limitation of viral-based gene delivery platforms. For example, adeno-associated virus (AAV) is limited to transgene lengths of approximately 4.7 kb, which precludes the incorporation of larger genes associated with disease [9].

Gene replacement therapy is expected to be most beneficial in the setting of pathogenic loss-of-function (LoF) variants. Nonsense, splice site, and frameshift variants are among the most common LoF variants in genetically determined cardiomyopathy and HF [10]. It is thought that these mutations generate truncated, non-functional proteins. However, the activity of nonsense mediated messenger RNA (mRNA) decay may prevent translation of these mutant proteins in the cell and instead generate a null allele [11]. Additionally, expressing the functional copy of gene may have salutary effects in the context of certain LoF missense variants associated with sarcomeric cardiomyopathy, which we discuss further in a later section of this article.

Somatic Genome Editing

Therapeutic genome editing involves modifying the endogenous deoxyribonucleic acid (DNA) sequence in somatic cells. In contrast to gene transfer, genome editing has the potential to permanently correct LoF and gain-of-function (GoF) pathogenic variants associated with HF and cardiomyopathy. Clustered regulatory interspaced palindromic repeats (CRISPR)-Cas9 is an immune defense system in bacteria that has been repurposed for eukaryotic genome editing in biomedical research [12]. Genome editing with CRISPR-Cas9 requires two fundamental components: a single guide RNA that specifically targets a DNA region of interest and a modified RNA-guided endonuclease (Cas9) that induces double-strand DNA breaks [13]. Following DNA repair by endogenous cellular machinery (homology directed repair in dividing cells or non-homologous end joining), gene knock-in or knockout is achieved [14]. The CRISPR-Cas9 system can edit the genome through targeted conversion, insertion, or deletion of DNA base pairs.

Further engineering the CRISPR-Cas9 has led to the development of base and prime editors, which can install targeted point mutations in the genome with higher efficiency compared to the conventional system [15, 16]. Base and prime editing does not rely on double-strand DNA breaks, occurs in the absence of a donor DNA template, and is active in non-dividing cells. This approach may be particularly beneficial for editing genomic DNA in the post-mitotic contractile cells of the heart and skeletal muscle [17]. While CRISPR-based therapeutic genome editing offers several advantages over gene replacement therapy, it has a few important drawbacks. Despite its relatively high precision in genome editing, there is a major concern for off-target activity and oncogenic potential. It is especially critical to ensure germline DNA, which is transmitted to offspring, is not edited in the process. There is accumulating evidence of host immune responses to the bacterial endonucleases [18–20]. Not only could this ultimately reduce the effectiveness of in vivo genome editing, but it may also cause host cytotoxicity and serious side effects in patients. Current CRISPR-based gene editing strategies also require the design and development of mutation-specific therapies, which is a lengthy and costly process.

Epigenome Editing

The CRISPR-Cas9 system has been further engineered to modulate the expression of endogenous genes without the requirement for DNA damage. This is accomplished by fusing transcriptional or epigenetic effector proteins to a catalytically inactive Cas9 (dCas9) and targeting the machinery to a DNA region of interest [21, 22]. In theory, this could be an effective approach to modulate the expression of genetic modifiers in the setting of disease. While RNA-guided dCas9 is capable of moderate gene repression without effector proteins by blocking RNA polymerase/transcription factor binding, direct fusion with Krüppel-associated box (KRAB) or four concatenated mSin3 interaction domains (SID4X) enables robust downregulation of endogenous gene expression [17]. In contrast, fusion of VP64, p65, or VPR activation domains to dCas9 enhances endogenous gene transcription [17].

Endogenous gene expression can also be manipulated by fusing dCas9 to effector proteins that modify epigenomic markers. For example, fusion of dCas9 to the catalytic domain of DNA (cytosine-5)-methyltransferase 3A (DNMT3A) has been shown to promote site-specific DNA methylation and subsequent repression of proximal genes [23, 24]. Fusion of dCas9 with the catalytic core of histone acetyltransferase p300 was shown to increase histone H3 lysine 27 acetylation, a marker of active gene enhancers, and up-regulate the expression of nearby target genes [25]. Alternatively, fusion of dCas9 with lysine-specific histone demethylase 1 (LSD1) has been shown to repress targeted gene expression by altering the levels of specific epigenome modifications at a nearby enhancer region [26]. In contrast to catalytically active Cas9 systems, a key advantage of potential therapies leveraging CRISPR-dCas9 is the ability to modulate gene expression in vivo without carrying the risks associated with directly altering the genetic code.

Messenger RNA Technologies

The COIVD-19 pandemic catalyzed the widespread development and implementation of mRNA technologies to combat disease. Messenger RNA medicines, which can be thought of programmable biological software, involve the synthesis and modification of mRNA molecules that encode proteins that stimulate immune response against infectious agents or that correct genetic defects underlying various diseases [27]. Owing to its versatility and relative ease of manufacturing, this innovative technology has the potential to revolutionize medical therapy across a wide spectrum of ailments. Although in early stages, mRNA-based medicines are also extending to therapeutic applications for cardiovascular disease [28]. In a phase 2a clinical trial, surgeons administered naked vascular endothelial growth factor (VEGF) mRNA via intramyocardial injection at thirty sites within ischemic regions in patients undergoing coronary artery bypass grafting (CABG) [29]. Subsequent analysis revealed decreased plasma brain natriuretic peptide (BNP) levels and increased walking distance on the treadmill, suggesting potential beneficial effects on cardiovascular function. While these results are encouraging, this approach may be further optimized by refining the delivery method and/or enhancing mRNA stability to durably reverse myocardial ischemia. Fibrosis is a pathological hallmark of heart disease and plays a key role in progression to heart failure. In 2022, an mRNA-based approach was evaluated for its potential effectiveness in reversing cardiac fibrosis in an in vivo preclinical model of heart injury [30]. In this elegant study, lipid nanoparticles containing mRNA molecules that encode a chimeric antigen receptor (CAR) were used to generate CAR T cells in mice, resulting in a population of therapeutic T lymphocytes that abolished activated fibroblasts, attenuated myocardial fibrosis, and restored cardiac function following injury. There is also an ongoing Phase 1 clinical trial by Moderna to evaluate the safety and tolerability an investigational mRNA-based therapeutic (mRNA-0184) for the treatment of heart failure (NCT05659264). Messenger RNA-0184 is an intravenously administered lipid nanoparticle formulation that contains modified mRNA encoding a human relaxin-2 fusion protein. Relaxin-2 is a naturally occurring hormone that has been shown to exert beneficial effects on cardiovascular remodeling and renal function. Together, these studies highlight the tremendous potential of harnessing mRNA technology to treat cardiovascular disease arising from diverse etiologies.

Delivery Modalities

Achieving efficient and targeted delivery of genetic medicines to the heart has historically represented a major hurdle thwarting the development of precision therapies for HF [31]. However, recent progress in viral- and non-viral-mediated gene delivery modalities is enabling unprecedented access to the cardiovascular system in a targeted manner.

Adenoviruses

Adenoviruses are non-enveloped viruses that are comprised of an icosahedral capsid [32]. The adenoviruses genome is 54 kilobases and is composed of double-stranded DNA. Adenoviruses have a few advantages over AAVs, such as the capacity to package larger transgenes and achieve higher rates of viral transduction. However, adenoviruses appear to be substantially more immunogenic and transgene expression is limited to a transient period [33]. Furthermore, administration of a therapeutic adenovirus led to the death of a patient with ornithine transcarbamylase deficiency due to toxicity associated with a systemic inflammatory response [34]. Consequently, momentum for developing gene therapy adenoviral vectors waned, and attention instead has focused on adeno-associated viruses (AAVs).

Adeno-Associated Viruses

Similar to adenoviruses, AAVs are non-enveloped vectors with an icosahedral capsid. However, in contrast to adenoviruses, AAVs contain a smaller (~ 4.7 kilobase) DNA genome that is single stranded [32]. Recombinant AAVs used for therapeutic purposes are rendered replication deficient and persist as non-integrating, extrachromosomal structures in the host cell, thereby providing stable transgene expression. While AAVs appear to display a lower immunogenic profile compared to adenoviruses and lentiviruses, it is not negligible. AAV has been shown to trigger the innate and adaptive immune systems accompanied by inflammation in the host [35–37]. The immunogenicity of AAVs can culminate in toxicity and reduced biologic effects. Furthermore, neutralizing anti-AAV antibodies are relatively prevalent in the general population and can cross-react between different serotypes [38]. Nevertheless, AAVs hold tremendous promise in serving as safe and effective delivery vehicles for precision genetic medicines in the setting of HF [39].

While naturally occurring serotypes like AAV9 exhibit relatively high cardiac and skeletal muscle tropism, recent advancements in AAV capsid engineering have led to the development of AAVs demonstrating unprecedented transduction efficiencies in striated muscle. Using directed evolution of AAV capsids, two independent groups recently reported the development of these next generation AAV variants dubbed “AAVMYO” and “MyoAAV” [40, 41] In murine and primates preclinical studies these myotropic capsids has enabled efficient delivery of therapeutic transgenes at significantly lower doses—up to 250 times lower than what is necessary for naturally occurring AAVs [42]. Advancements in capsid engineering such as these are critical to improving efficacy and lowering the cost of good for potential gene therapies.

Lentiviruses

Lentiviruses are enveloped, single-stranded RNA vectors that can be harnessed for gene therapy applications. They are capable of efficiently transducing dividing and post-mitotic cells and can accommodate transgenes up to approximately 9 kilobases in size [32]. However, a major limitation is the potential risk for insertional mutagenesis, as lentiviral vectors randomly integrate into coding regions of the host genome to induce long term transgene expression [43, 44]. While this risk may be minimal in terminally differentiated cells of the heart and skeletal muscle, it is not zero. Self-inactivating lentiviral vectors have been developed to further minimize this risk [45], but with availability of safer alternatives such as AAVs, we are not aware of any current reports on lentiviruses being developed for in vivo cardiovascular gene therapy.

Non-Viral

To circumvent the concern of immunogenicity and limited packaging size associated with viral-based gene delivery vehicles, non-viral vectors have been developed for use in gene therapy. Non-viral vectors include inorganic nanoparticles, exosomes, cationic polymers, and lipid nanoparticles, as well as combinations thereof [46]. In contrast to existing virus-based modalities, non-viral vectors tend to be easier to scale up for mass production. To confer tissue specificity of non-viral vectors, specific targeting ligands are conjugated to the surface of the particles [47]. This is a rapidly expanding area of research and development, especially for RNA-based genetic medicines [48]. Indeed, mRNA-based vaccines for the COVID-19 pandemic were formulated with lipid nanoparticles and were clinically proven to be relatively safe and effective [49]. Recent studies have shown encouraging results for in vivo delivery of gene editing machinery using lipid nanoparticles to treat disorders of the liver, including amyloid disease and hypercholesterolemia. [50, 51] As the field makes additional progress in the future, non-viral vectors may have increased utility for cardiovascular gene therapy. Current limitations include the inability to effectively deliver RNA therapeutics to striated muscle.

Targets for Cardiovascular Gene Therapy

HF is a complex clinical syndrome influenced by the interplay of genetic and environmental factors [4]. Genetic contributions can be subdivided into monogenic and polygenic cardiac disorders [10]. Based on therapeutic tractability and unmet need, cardiomyopathies and muscular dystrophies comprise most of the current targets for HF gene therapy, which we outline below.

Barth Syndrome

Barth syndrome is a rare and potentially lethal disorder characterized by cardiomyopathy, skeletal muscle weakness, neutropenia, organic aciduria, growth delay, and exercise intolerance [52]. It affects approximately 1 in 0.3 to 0.4 million live births and primarily males [53]. It is caused by pathogenic mutations in the Tafazzin gene (TAZ), which is located on the X chromosome, and encodes a protein (TAZ) located in the inner mitochondrial membrane [52]. TAZ is an enzyme essential for the biogenesis of cardiolipin, a phospholipid important for maintaining mitochondrial structure and lipid metabolism [54]. Cardiomyopathy and neutropenia represent the leading causes of mortality in patients with Barth syndrome, and there are no targeted therapies currently available [55]. A preclinical study recently tested the efficacy of an AAV-based TAZ gene transfer therapy in a knock-out mouse model of Barth syndrome [56]. Neonatal Taz knock-out mice that received high-dose AAV9 displayed significantly increased survival compared to untreated Taz knock-out mice. Furthermore, the treated mice showed protection against cardiac dysfunction and reduced myocardial fibrosis. Results from additional experiments suggested that increased survival was primarily due to TAZ protein replacement in skeletal muscle. Based on this proof-of-concept study, gene transfer may be a viable approach for treating Barth syndrome.

Danon Disease

Danon disease is a rare X-linked lysosomal storage disorder characterized by progressive hypertrophic cardiomyopathy (HCM), skeletal muscle weakness, liver pathology, and cognitive disability [57]. It is a monogenic disease caused by loss-of-function mutations in the lysosomal-associated membrane protein 2 gene (LAMP2) [58]. LAMP-2 protein deficiency leads to impaired autophagic flux and subsequent accumulation of autophagic vacuoles in tissues [59]. While the exact prevalence is uncertain, it has been reported that 1–4% of patients with hypertrophic cardiomyopathy have a LAMP2 variant, necessitating an unmet need to develop precision therapies [60, 61]. In 2020, a preclinical study evaluated the efficacy of an AAV9-based LAMP2B gene transfer therapy in a Lamp2b knock-out mouse model of Danon disease [62]. Adult and adolescent knock-out mice treated with systemic administration of AAV9-LAMP2B demonstrated increased survival, cardiac function, and autophagic flux and reduced transaminases compared to untreated control mice. This proof-of-concept study paved the way for the development of an AAV9-based human gene therapy vector by (RP-A501) that is currently being tested in a phase 1 clinical trials (NCT03882437), with plans to begin phase 2 clinical trials by the end of 2023.

Sarcomeric Cardiomyopathy

Autosomal dominant mutations in the genes encoding sarcomeric proteins, the contractile regulatory proteins in striated muscle cells, are a leading cause of inherited cardiomyopathies, including HCM, dilated cardiomyopathy (DCM), and restrictive cardiomyopathy (RCM) [63]. The genes strongly associated with sarcomeric HCM are myosin heavy chain (MYH7) and myosin binding protein C (MYBPC3), whereas mutations in the titin gene (TTN) represent the leading cause of sarcomeric DCM. Mutations in the genes encoding thin filament proteins, including troponin subunits (TNNI3, TNNT2, TNNC1) and alpha tropomyosin (TPM1) are also tightly associated with genetic cardiomyopathy [64]. In two recent studies reported by independent groups, CRISPR-Cas9 adenine base editing was successfully used to prevent the development and progression of HCM in well-established mouse models [65, 66]. In another study using a Mybpc3 knock out mouse model of HCM, single dose administration with AAV9-MYBPC3 gene transfer in neonatal mice was sufficient to prevent the development of HCM [67]. This proof-of-concept study paved the way for the development of an AAV9-MBYPC3 gene transfer therapy vector (TN-201) that is currently being tested in a phase 1 clinical trial to assess safety and efficacy (NCT05112237). AAV gene transfer may be effective for treating certain missense mutations linked to cardiomyopathy. In theory, delivery of an exogenous wild type sarcomeric protein in the setting of a diseased allele could potentially outcompete and stoichiometrically replace the endogenous mutant protein, thereby normalizing contractile function [11]. While additional studies are needed to assess this possibility, it is conceivable that this approach may be viable for treating a large proportion of patients with sarcomeric cardiomyopathy.

BAG3 Cardiomyopathy

Mutations in the BCL2-associated athanogene 3 (BAG3) gene have been associated with the development of DCM in humans [68]. The majority are truncating or deletion variants, resulting in reduced BAG3 protein levels. Decreased levels of BAG3 protein are also observed in the setting of end-stage HF caused by myocardial infarction [69]. Low levels of BAG3 protein are associated with impaired sarcomere contractility and decreased myofilament protein turnover [70]. Evidence from several preclinical studies supports the potential use of gene therapy to treat cardiomyopathy and failure [71]. For example, AAV9-mediated gene transfer of BAG3 in haplo-insufficient mice suggested beneficial effects on contractile function [72]. In another study, mice with HF secondary to experimental myocardial infarction were treated with AAV9-BAG3, leading to increased myofilament protein turnover, and restoration of myocardial contractility [73]. More recently, a small study in healthy Yucatan mini pigs revealed that low-dose AAV9-BAG3 gene transfer by catheter-guided retrograde coronary sinus infusion resulted in widespread myocardial transduction [74], pointing to a potentially viable approach to efficiently deliver BAG3 transgene in the setting of cardiomyopathy and HF.

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a severe, X-linked recessive neuromuscular disorder caused by mutations in the dystrophin gene (DMD) that lead to dystrophin protein deficiency [75]. Dystrophin maintains the structural integrity of the sarcolemma in striated muscle cells of the heart and skeletal muscle. Patients with DMD exhibit progressive skeletal muscle weakness, DCM, and often death by the third decade of life [76]. While the enormous size of the full-length dystrophin coding sequence precludes it from being packaged into a viral vector, innovative strategies have been developed to enable gene therapy for DMD [77]. The creation of mini/micro-dystrophin constructs, which contain only the critical domains of full-length dystrophin, have shown promise for restoring muscle structure and function in the setting of DMD.

In June of 2023, the U.S. Food and Drug Administration (FDA) granted approval of the first AAV gene therapy product (delandistrogene moxeparvovec, tradename ELEVIDYS) for the treatment of pediatric patients, 4 to 5 years of age, with DMD [78]. This decision was based on evidence of increased micro-dystrophin protein expression in treated patients from phase 1/2 clinical trials. ELEVIDYS is a recombinant AAV, serotype rh74, containing codon optimized human micro-dystrophin under the control of the muscle specific MHCK7 promoter [79]. Proof-of-concept studies have also reported the use of AAV-mediated base and prime editing in mouse models of DMD [80–82]. In addition to AAV gene therapy methods, there are 4 currently FDA approved exon-skipping antisense oligonucleotide (ASO) therapies for DMD [83], although these are mutation specific and require repeated dosing. Furthermore, it is unclear whether exon-skipping strategies improve myocardial function.

Fabry Disease

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the alpha galactosidase A gene (GLA) [84]. These mutations typically reduce the enzymatic activity of alpha galactosidase A protein, resulting in lysosomal accumulation of glycosphingolipid substrates such as cerebroside trihexosides. Fabry disease affects multiple organ systems, frequently culminating in renal failure, severe heart disease, cerebrovascular events, and premature death [85, 86]. There are several ongoing studies assessing the safety and efficacy of gene therapy for Fabry disease. AVR-RD-01 is an investigational ex vivo gene therapy in which a patient’s own hematopoietic stem cells are genetically modified with a lentivirus to express functional alpha galactosidase A and then transplanted back into the patient (NCT03454893). Unfortunately, patient enrollment for this study was terminated owing to poor grafting in 5 participants in the open-label Phase 2 clinical trial. ST-920 (isaralgagene civaparvovec) is a single-dose AAV gene transfer investigational therapy currently in Phase 1/2 clinical trials to assess safety and tolerability in subjects with Fabry disease (NCT04046224). It is a recombinant AAV2/6 vector containing the full length human GLA coding sequence. Preliminary results from the trial suggest a favorable impact on progression of neuropathy in Fabry patients, and the developers intend to move forward with Phase 3 clinical trials by the end of 2023. 4D-310 is another single-dose intravenous AAV-based investigational gene transfer therapy for Fabry disease currently in a Phase 1/2 clinical trials to assess safety, tolerability, and pharmacodynamics (NCT04519749). 4D-310 is comprised of an engineered cardiotropic AAV vector (C102) and transgene cassette containing codon-optimized full-length human GLA driven by the CAG promoter. In February 2023, the study was placed on hold by the FDA due to reports of atypical hemolytic uremic syndrome in 3 of the 6 participants who received the treatment. In September of 2023, a pre-clinical study evaluated an AAV2/8 human GLA gene transfer approach in a mouse model of Fabry disease [87]. Upon systemic administration, the treated mice showed increased GLA enzyme activity in plasma and relevant tissues, which was maintained for up to 38 weeks. These findings further support the development of AAV-based precision gene therapies for Fabry disease.

Transthyretin Amyloid Cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a disorder characterized by extracellular deposition of misfolded transthyretin protein that accumulates primarily in the myocardium and peripheral nerves [88]. It can be caused by pathogenic variants in the TTR gene, referred to as hereditary ATTR-CM, or occur as an age-related phenomenon, referred to as wild-type ATTR-CM. Both forms of ATTR-CM can lead to severe HF [89]. Although small interfering RNA (siRNA) and ASO-based medicines are currently available on the market, these therapies require long-term administration to sustain benefit [90]. A new in vivo CRISPR-based gene editing therapy (NTLA-2001) is currently being investigated for the treatment of ATTR-CM (NCT04601051). NTLA-2001 is delivered by a proprietary lipid nanoparticle formulation that is engineered to be internalized by the low-density lipoprotein receptor on hepatocytes, CRISPR-Cas9 editing induces a frameshift mutation in the TTR gene, leading to decreased transthyretin protein production. Preclinical studies in rodent models and nonhuman primates demonstrated that a single intravenous infusion of NTLA-2001 led to reductions in transthyretin levels that persisted over at least a 12-month period [91, 92]. In August 2021, interim results reported that NTLA-2001 appears to be effective at reducing serum transthyretin levels in humans, with only mild adverse events [92]. In October of 2023, the FDA cleared the Investigational New Drug (IND) application for NTLA-2001, allowing the initiation of a pivotal Phase 3 clinical trials in the U.S. by the end of the year.

Limb-Girdle Muscular Dystrophy

Limb-girdle muscular dystrophy (LGMD) represents a group of progressive neuromuscular disorders that lead to profound skeletal muscle weakness and wasting [93]. There are currently no targeted treatments available and, as a monogenic disorder, LGMD is readily amenable to gene therapy. Severe forms of LGMD, such as LGMD type 2E (LGMD2E) are associated with cardiomyopathy and arrhythmias [94, 95]. LGMD2E is caused by mutations in the beta sarcoglycan gene (SGCB), leading to beta sarcoglycan deficiency [96]. SRP-9003 (bidridistrogene xeboparvovec) is an investigational gene transfer therapy currently being tested in Phase 1/2 clinical trials for LGDM2E (NCT03652259). SRP-9003 uses AAVrh74 vector and is designed to deliver a functional copy of beta sarcoglycan under the control of the muscle-specific MHCK7 promoter [97]. Recent preclinical studies in mice have also shown promise for using AAV-based gene transfer therapy to treat LGMD type 2C/R5, which is caused by mutations in the gamma sarcoglycan gene (SGCG) that lead to protein deficiency [98]. Restoration of gamma sarcoglycan gene and protein expression was observed in skeletal muscles and heart. Improvements in skeletal muscle function were also observed in the treated mice. These results further support the concept of using gene therapies for muscular dystrophies associated with cardiac dysfunction.

Hurler Syndrome

Mucopolysaccharidosis type I (Hurler syndrome) is an inherited lysosomal storage disease characterized by hepatosplenomegaly, musculoskeletal abnormalities, retinal degeneration, and cardiomyopathy [99]. Early mortality in patients with Hurler syndrome is typically associated with cardiopulmonary failure. It is caused by mutations in the gene encoding alpha-L-iduronidase (IDUA), leading to enzyme deficiency and accumulation of glycosaminoglycan substrates [100]. While several gene-based strategies to treat Hurler syndrome have been previously reported, these approaches are limited by potential loss of the episomal transgene, risk of insertional mutagenesis, and lack of precise targeting [101]. More recently, a new AAV9-based CRISPR adenine base editing therapy was tested in a preclinical mouse model and showed encouraging results [102]. In utero base editing in a mouse model of Hurler syndrome led to long-term correction of the pathogenic mutation in the heart and liver along with improved survival. The treated mice displayed amelioration of pathology in multiple organs including the heart, brain, and liver. Importantly, there were also significant improvements in cardiac and skeletal muscle function, as well as neurobehavioral phenotypes [102].

Marfan Syndrome

Marfan syndrome is among the most common inherited disorders of connective tissue [103]. Marfan syndrome is caused by mutations in the fibrillin-1 gene (FBN1), which impacts multiple organ systems, including the skeleton, eyes, heart, lungs, and blood vessels. Cardiovascular disease (aortic root dissection, DCM, and HF) accounts for more than 90% of early deaths in patients with Marfan syndrome, necessitating a need for targeted therapies to treat this disorder [104]. A recent proof-of-concept study showed the possibility of using base editing in embryos as an early therapeutic intervention for Marfan syndrome [105]. The results showed a correction efficiency of roughly 89%, with no detection of indels or off-target editing. Therefore, base editing may represent a potential strategy for treating Marfan syndrome.

Progeria (Hutchinson-Gilford Syndrome)

Hutchinson-Gilford progeria syndrome (HGPS) is a rare, autosomal dominant premature aging syndrome caused by mutations in the LMNA gene [106]. Early death in children with HGPS is associated with accelerated cardiovascular disease, including myocardial infarction and stroke. In a recent proof-of-concept study, adenine base editing was used to correct a HGPS mutation with high efficiency in cultured fibroblasts from patients and in a mouse model of HGPS [107]. In a mouse model of Progeria, a single dose of the base editor delivered by AAV9 led to correction of the pathogenic variant in various organs six months post-injection. Furthermore, the treated mice showed rescue of vascular pathology and significantly improved the median lifespan. This early preclinical study demonstrates the potential power of harnessing precision gene editing to treat HGPS.

Friedreich’s Ataxia

Friedreich’s ataxia is an autosomal recessive disorder with a prevalence of 1 in 40,000 [108]. It is characterized clinically by progressive neurodegeneration, cerebellar ataxia, cardiomyopathy, and heart failure [108]. At the molecular level, a genetic defect in the frataxin gene (FXN) leads to frataxin protein deficiency and mitochondrial dysfunction [109]. There is an ongoing Phase 1 clinical trial to assess the safety and preliminary efficacy of an AAV-based gene transfer approach (AAVrh.10hFXN) to treat Friedreich’s ataxia-associated cardiomyopathy (NCT05302271). This study commenced in February 2022 and the clinical trial is actively recruiting participants. The AAVrh.10hFXN vector is administered intravenously and carries the coding sequence for human FXN. In preclinical studies, AAV gene therapy approaches led to correction of cardiomyopathy phenotypes in mouse models of Friedreich’s ataxia [110, 111]. Based on these encouraging proof-of-concept studies, gene transfer may represent a viable therapeutic approach for patients with cardiomyopathy caused by Friedreich’s ataxia [112].

Pompe Disease

Pompe disease is an inherited lysosomal storage disorder caused by recessive mutations in the acid alpha glucosidase gene (GAA) [113]. These mutations result in alpha glucosidase protein deficiency and excess lysosomal glycogen accumulation in cardiac, skeletal, and smooth muscles. Infantile onset Pompe disease is clinically characterized by severe HCM, hypotonia, and respiratory insufficiency [114]. Preclinical studies have supported the concept of harnessing gene therapy to treat Pompe disease [115]. Without treatment, this disorder is often fatal within 1 year of age, necessitating a need to develop precision therapies. There is an ongoing Phase 1/2 clinical trial to evaluate the safety and efficacy of AT845, an AAV8 vector containing a functional copy of human GAA delivered by intravenous infusion, in adult patients with late-onset Pompe disease (NCT04174105). A separate Phase 1 clinical trial is also assessing the safety and bioactivity of ACTUS-101 in patients with late-onset Pompe disease (NCT03533673) [116]. ACTUS-101 is an AAV2/8 vector containing a functional copy of GAA for expressing hepatocytes. SPK-3006 is a third investigational gene therapy in Phase 1/2 clinical trials to evaluate the safety, tolerability, and efficacy in patients with late-onset Pompe disease (NCT04093349). SPK-3006 is a recombinant liver-directed AAV vector designed to drive the expression of secretable GAA protein upon a single intravenous infusion. In contrast to enzyme-replacement therapy, which requires repeated administration, these potential AAV precision gene therapies may have the potential to provide long-term for patients with Pompe disease.

Concluding Remarks

Human gene therapy holds tremendous potential for revolutionary treatments in cardiovascular medicine [117]. As the technologies continue to advance and undergo refinement, opportunities for precise targeting of these devastating disorders will likely expand. Gene transfer and gene editing approaches have unequivocally proven therapeutically effective in preclinical models for heart failure, thereby supporting progression for further evaluation in clinical trials [118]. While some of these investigational therapies have already shown benefit in humans, there remains substantial challenges that necessitate cautious navigation. Safety is the most crucial challenge currently facing the field. The death of a Duchenne muscular dystrophy (DMD) patient in a recent clinical trial using AAV-based gene therapy serves as sobering reminder that minimizing risks of these interventions must occur before widespread clinical implementation [119].

Improving the safety of human gene therapies must be a priority; this will be mandated if the hope of using AAV as an early intervention or for diseases less morbid than DMD. Further research is necessary to better understand the host immune response to the viral vector. The discovery of new capsid variants with increased cardiac tropism may mitigate this risk by significantly lowering the required dose to achieve efficacy. Another issue facing viral-based gene therapies is the potential presence of pre-existing immunity in patients, which could reduce the effectiveness of these drugs and prevent redosing. This problem may be resolved in the future as non-viral delivery such as lipid nanoparticles methods continue to emerge. Immunogenicity is also germane to CRISPR-based therapies, as the Cas9 endonuclease is derived from bacteria.

Preventing transgene expression in unwanted tissues represents another challenge. While the use of tissue-specific promoters and other regulatory elements lowers this risk, it is not zero. The development of synthetic promoters and implementation of novel regulatory elements into therapeutic constructs may provide an avenue for addressing this obstacle. In contrast to gene transfer therapy, gene editing carries the unique risk of off-target mutagenesis, whereby new mutations are introduced at undesired genetic loci. Use of catalytically inactive or higher fidelity Cas proteins have the potential to minimize this risk.

While studies in pre-clinical models suggest durability of gene therapies and absence of negative long-term effects, it is unclear whether this will translate to humans. Meticulous design of clinical trials and close, consistent monitoring is of paramount importance as gene therapies move to the clinical setting. The high cost associated with research, development, and manufacturing of these innovative medicines introduces challenges surrounding affordability and access. Overcoming these myriad challenges requires multidisciplinary collaboration among regulatory agencies, scientists, ethicists, healthcare professionals, and active engagement with patients and families in need.

Author Contributions

E.A. secured funding for this work. J.J. drafted an outline and wrote the main manuscript text with help and supervision from E.A. E.A. and J.J. edited the manuscript and reviewed the manuscript prior to submission.

Funding

Eric Adler reports grants or contracts from the California Institute of Regenerative Medicine and the National Institutes of Health (R01HL155281).

Data Availability

No datasets were generated or analysed during the current study.

Declarations

Competing interests

Jamie Johnston was formerly employed at Kate Therapeutics and reports owning stock or stock options. Eric Adler is the Chief Scientific Officer at Lexeo Therapeutics and a shareholder in Rocket Pharmaceuticals. He also reports the following: consulting fees from Abiomed and Abbott; payment for expert testimony from AstraZeneca; participation on a Data Safety Monitoring Board or Advisory Board for Rocket Pharmaceuticals, Cytokinetics, and Kiniska; leadership or fiduciary role in Lexeo Therapeutics, Heart Failure Society of America, and American Heart Association; and stock or stock options for Lexeo Therapeutics, Rocket Pharmaceuticals, and Papillion Therapeutics.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflicts of Interest

Jamie Johnston was formerly employed at Kate Therapeutics and reports owning stock or stock options. Eric Adler is the Chief Scientific Officer at Lexeo Therapeutics and a shareholder in Rocket Pharmaceuticals. He also reports the following: consulting fees from Abiomed and Abbott; payment for expert testimony from AstraZeneca; participation on a Data Safety Monitoring Board or Advisory Board for Rocket Pharmaceuticals, Cytokinetics, and Kiniska; leadership or fiduciary role in Lexeo Therapeutics, Heart Failure Society of America, and American Heart Association; and stock or stock options for Lexeo Therapeutics, Rocket Pharmaceuticals, and Papillion Therapeutics.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Tsao CW Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association Circulation 2022 145 8 e153 e639 10.1161/CIR.0000000000001052 35078371
Tsao CW, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153–639.35078371 10.1161/CIR.0000000000001052
2. Savarese G Global burden of heart failure: a comprehensive and updated review of epidemiology Cardiovasc Res 2023 118 17 3272 3287 10.1093/cvr/cvac013 35150240
Savarese G, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–87.35150240 10.1093/cvr/cvac013
3. Kieserman JM Current Landscape of Heart Failure Gene Therapy J Am Heart Assoc 2019 8 10 e012239 10.1161/JAHA.119.012239 31070089
Kieserman JM, et al. Current Landscape of Heart Failure Gene Therapy. J Am Heart Assoc. 2019;8(10):e012239.31070089 10.1161/JAHA.119.012239
4. Heidenreich PA 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation 2022 145 18 e895 e1032 35363499
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032.35363499
5. Robinson EL Port JD Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease JACC Basic Transl Sci 2022 7 9 956 969 10.1016/j.jacbts.2022.02.003 36317129
Robinson EL, Port JD. Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease. JACC Basic Transl Sci. 2022;7(9):956–69.36317129 10.1016/j.jacbts.2022.02.003
6. Lucas T Bonauer A Dimmeler S RNA Therapeutics in Cardiovascular Disease Circ Res 2018 123 2 205 220 10.1161/CIRCRESAHA.117.311311 29976688
Lucas T, Bonauer A, Dimmeler S. RNA Therapeutics in Cardiovascular Disease. Circ Res. 2018;123(2):205–20.29976688 10.1161/CIRCRESAHA.117.311311
7. Bejar N Tat TT Kiss DL RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases Curr Atheroscler Rep 2022 24 5 307 321 10.1007/s11883-022-01007-9 35364795
Bejar N, Tat TT, Kiss DL. RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases. Curr Atheroscler Rep. 2022;24(5):307–21.35364795 10.1007/s11883-022-01007-9
8. Skopenkova VV Egorova TV Bardina MV Muscle-Specific Promoters for Gene Therapy Acta Naturae 2021 13 1 47 58 10.32607/actanaturae.11063 33959386
Skopenkova VV, Egorova TV, Bardina MV. Muscle-Specific Promoters for Gene Therapy. Acta Naturae. 2021;13(1):47–58.33959386 10.32607/actanaturae.11063
9. Naso MF Adeno-Associated Virus (AAV) as a Vector for Gene Therapy BioDrugs 2017 31 4 317 334 10.1007/s40259-017-0234-5 28669112
Naso MF, et al. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017;31(4):317–34.28669112 10.1007/s40259-017-0234-5
10. Cahill TJ Ashrafian H Watkins H Genetic cardiomyopathies causing heart failure Circ Res 2013 113 6 660 675 10.1161/CIRCRESAHA.113.300282 23989711
Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013;113(6):660–75.23989711 10.1161/CIRCRESAHA.113.300282
11. Helms AS Thompson AD Day SM Translation of New and Emerging Therapies for Genetic Cardiomyopathies JACC Basic Transl Sci 2022 7 1 70 83 10.1016/j.jacbts.2021.07.012 35128211
Helms AS, Thompson AD, Day SM. Translation of New and Emerging Therapies for Genetic Cardiomyopathies. JACC Basic Transl Sci. 2022;7(1):70–83.35128211 10.1016/j.jacbts.2021.07.012
12. Wang JY Doudna JA CRISPR technology: A decade of genome editing is only the beginning Science 2023 379 6629 eadd864 10.1126/science.add8643
Wang JY, Doudna JA. CRISPR technology: A decade of genome editing is only the beginning. Science. 2023;379(6629):eadd864.10.1126/science.add8643
13. Wright AV Nunez JK Doudna JA Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering Cell 2016 164 1–2 29 44 10.1016/j.cell.2015.12.035 26771484
Wright AV, Nunez JK, Doudna JA. Biology and Applications of CRISPR Systems: Harnessing Nature’s Toolbox for Genome Engineering. Cell. 2016;164(1–2):29–44.26771484 10.1016/j.cell.2015.12.035
14. Yeh CD Richardson CD Corn JE Advances in genome editing through control of DNA repair pathways Nat Cell Biol 2019 21 12 1468 1478 10.1038/s41556-019-0425-z 31792376
Yeh CD, Richardson CD, Corn JE. Advances in genome editing through control of DNA repair pathways. Nat Cell Biol. 2019;21(12):1468–78.31792376 10.1038/s41556-019-0425-z
15. Anzalone AV Search-and-replace genome editing without double-strand breaks or donor DNA Nature 2019 576 7785 149 157 10.1038/s41586-019-1711-4 31634902
Anzalone AV, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149–57.31634902 10.1038/s41586-019-1711-4
16. Gaudelli NM Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage Nature 2017 551 7681 464 471 10.1038/nature24644 29160308
Gaudelli NM, et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464–71.29160308 10.1038/nature24644
17. Nishiga M The use of new CRISPR tools in cardiovascular research and medicine Nat Rev Cardiol 2022 19 8 505 521 10.1038/s41569-021-00669-3 35145236
Nishiga M, et al. The use of new CRISPR tools in cardiovascular research and medicine. Nat Rev Cardiol. 2022;19(8):505–21.35145236 10.1038/s41569-021-00669-3
18. Ewaisha R Anderson KS Immunogenicity of CRISPR therapeutics-Critical considerations for clinical translation Front Bioeng Biotechnol 2023 11 1138596 10.3389/fbioe.2023.1138596 36873375
Ewaisha R, Anderson KS. Immunogenicity of CRISPR therapeutics-Critical considerations for clinical translation. Front Bioeng Biotechnol. 2023;11:1138596.36873375 10.3389/fbioe.2023.1138596
19. Gough V Gersbach CA Immunity to Cas9 as an Obstacle to Persistent Genome Editing Mol Ther 2020 28 6 1389 1391 10.1016/j.ymthe.2020.05.007 32428441
Gough V, Gersbach CA. Immunity to Cas9 as an Obstacle to Persistent Genome Editing. Mol Ther. 2020;28(6):1389–91.32428441 10.1016/j.ymthe.2020.05.007
20. Hakim CH Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models Nat Commun 2021 12 1 6769 10.1038/s41467-021-26830-7 34819506
Hakim CH, et al. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat Commun. 2021;12(1):6769.34819506 10.1038/s41467-021-26830-7
21. Gilbert LA Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation Cell 2014 159 3 647 661 10.1016/j.cell.2014.09.029 25307932
Gilbert LA, et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2014;159(3):647–61.25307932 10.1016/j.cell.2014.09.029
22. Qi LS Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression Cell 2013 152 5 1173 1183 10.1016/j.cell.2013.02.022 23452860
Qi LS, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173–83.23452860 10.1016/j.cell.2013.02.022
23 Liu XS Editing DNA Methylation in the Mammalian Genome Cell 2016 167 1 233 247 e17 10.1016/j.cell.2016.08.056 27662091
Liu XS, et al. Editing DNA Methylation in the Mammalian Genome. Cell. 2016;167(1):233-247 e17.27662091 10.1016/j.cell.2016.08.056
24 Amabile A Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing Cell 2016 167 1 219 232 e14 10.1016/j.cell.2016.09.006 27662090
Amabile A, et al. Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. Cell. 2016;167(1):219-232 e14.27662090 10.1016/j.cell.2016.09.006
25. Hilton IB Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers Nat Biotechnol 2015 33 5 510 517 10.1038/nbt.3199 25849900
Hilton IB, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol. 2015;33(5):510–7.25849900 10.1038/nbt.3199
26. Kearns NA Functional annotation of native enhancers with a Cas9-histone demethylase fusion Nat Methods 2015 12 5 401 403 10.1038/nmeth.3325 25775043
Kearns NA, et al. Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods. 2015;12(5):401–3.25775043 10.1038/nmeth.3325
27. Qin S mRNA-based therapeutics: powerful and versatile tools to combat diseases Signal Transduct Target Ther 2022 7 1 166 10.1038/s41392-022-01007-w 35597779
Qin S, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther. 2022;7(1):166.35597779 10.1038/s41392-022-01007-w
28. Cooke JP Youker KA Future Impact of mRNA Therapy on Cardiovascular Diseases Methodist Debakey Cardiovasc J 2022 18 5 64 73 10.14797/mdcvj.1169 36561087
Cooke JP, Youker KA. Future Impact of mRNA Therapy on Cardiovascular Diseases. Methodist Debakey Cardiovasc J. 2022;18(5):64–73.36561087 10.14797/mdcvj.1169
29. Anttila V Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting Mol Ther 2023 31 3 866 874 10.1016/j.ymthe.2022.11.017 36528793
Anttila V, et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Mol Ther. 2023;31(3):866–74.36528793 10.1016/j.ymthe.2022.11.017
30. Rurik JG CAR T cells produced in vivo to treat cardiac injury Science 2022 375 6576 91 96 10.1126/science.abm0594 34990237
Rurik JG, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91–6.34990237 10.1126/science.abm0594
31. Cannata A Gene Therapy for the Heart Lessons Learned and Future Perspectives Circ Res 2020 126 10 1394 1414 10.1161/CIRCRESAHA.120.315855 32379579
Cannata A, et al. Gene Therapy for the Heart Lessons Learned and Future Perspectives. Circ Res. 2020;126(10):1394–414.32379579 10.1161/CIRCRESAHA.120.315855
32. Rincon MY VandenDriessche T Chuah MK Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation Cardiovasc Res 2015 108 1 4 20 10.1093/cvr/cvv205 26239654
Rincon MY, VandenDriessche T, Chuah MK. Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res. 2015;108(1):4–20.26239654 10.1093/cvr/cvv205
33. Schiedner G Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity Nat Genet 1998 18 2 180 183 10.1038/ng0298-180 9462752
Schiedner G, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 1998;18(2):180–3.9462752 10.1038/ng0298-180
34. Raper SE Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer Mol Genet Metab 2003 80 1–2 148 158 10.1016/j.ymgme.2003.08.016 14567964
Raper SE, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1–2):148–58.14567964 10.1016/j.ymgme.2003.08.016
35. Calcedo R Wilson JM Humoral Immune Response to AAV Front Immunol 2013 4 341 10.3389/fimmu.2013.00341 24151496
Calcedo R, Wilson JM. Humoral Immune Response to AAV. Front Immunol. 2013;4:341.24151496 10.3389/fimmu.2013.00341
36. Ronzitti G Gross DA Mingozzi F Human Immune Responses to Adeno-Associated Virus (AAV) Vectors Front Immunol 2020 11 670 10.3389/fimmu.2020.00670 32362898
Ronzitti G, Gross DA, Mingozzi F. Human Immune Responses to Adeno-Associated Virus (AAV) Vectors. Front Immunol. 2020;11:670.32362898 10.3389/fimmu.2020.00670
37. Shirley JL Immune Responses to Viral Gene Therapy Vectors Mol Ther 2020 28 3 709 722 10.1016/j.ymthe.2020.01.001 31968213
Shirley JL, et al. Immune Responses to Viral Gene Therapy Vectors. Mol Ther. 2020;28(3):709–22.31968213 10.1016/j.ymthe.2020.01.001
38. Mendell JR Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations Mol Ther Methods Clin Dev 2022 25 74 83 10.1016/j.omtm.2022.02.011 35356756
Mendell JR, et al. Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations. Mol Ther Methods Clin Dev. 2022;25:74–83.35356756 10.1016/j.omtm.2022.02.011
39. Zhang H AAV-mediated gene therapy: Advancing cardiovascular disease treatment Front Cardiovasc Med 2022 9 952755 10.3389/fcvm.2022.952755 36061546
Zhang H, et al. AAV-mediated gene therapy: Advancing cardiovascular disease treatment. Front Cardiovasc Med. 2022;9:952755.36061546 10.3389/fcvm.2022.952755
40 Tabebordbar M Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species Cell 2021 184 19 4919 4938 e22 10.1016/j.cell.2021.08.028 34506722
Tabebordbar M, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021;184(19):4919-4938 e22.34506722 10.1016/j.cell.2021.08.028
41. Weinmann J Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants Nat Commun 2020 11 1 5432 10.1038/s41467-020-19230-w 33116134
Weinmann J, et al. Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat Commun. 2020;11(1):5432.33116134 10.1038/s41467-020-19230-w
42. Bonnemann CG Designer AAV muscle up Cell 2021 184 19 4845 4847 10.1016/j.cell.2021.08.031 34534462
Bonnemann CG. Designer AAV muscle up. Cell. 2021;184(19):4845–7.34534462 10.1016/j.cell.2021.08.031
43. Ranzani M Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer Nat Methods 2013 10 2 155 161 10.1038/nmeth.2331 23314173
Ranzani M, et al. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods. 2013;10(2):155–61.23314173 10.1038/nmeth.2331
44. Papayannakos C Daniel R Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy Gene Ther 2013 20 6 581 588 10.1038/gt.2012.88 23171920
Papayannakos C, Daniel R. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy. Gene Ther. 2013;20(6):581–8.23171920 10.1038/gt.2012.88
45. Zufferey R Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery J Virol 1998 72 12 9873 9880 10.1128/JVI.72.12.9873-9880.1998 9811723
Zufferey R, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72(12):9873–80.9811723 10.1128/JVI.72.12.9873-9880.1998
46. Wang C Emerging non-viral vectors for gene delivery J Nanobiotechnology 2023 21 1 272 10.1186/s12951-023-02044-5 37592351
Wang C, et al. Emerging non-viral vectors for gene delivery. J Nanobiotechnology. 2023;21(1):272.37592351 10.1186/s12951-023-02044-5
47 Ramamoorth M Narvekar A Non viral vectors in gene therapy- an overview J Clin Diagn Res 2015 9 1 GE01 6 25738007
Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res. 2015;9(1):GE01-6.25738007
48. Paunovska K Loughrey D Dahlman JE Drug delivery systems for RNA therapeutics Nat Rev Genet 2022 23 5 265 280 10.1038/s41576-021-00439-4 34983972
Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23(5):265–80.34983972 10.1038/s41576-021-00439-4
49. Schoenmaker L mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability Int J Pharm 2021 601 120586 10.1016/j.ijpharm.2021.120586 33839230
Schoenmaker L, et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021;601:120586.33839230 10.1016/j.ijpharm.2021.120586
50. Wei T Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing Nat Commun 2020 11 1 3232 10.1038/s41467-020-17029-3 32591530
Wei T, et al. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020;11(1):3232.32591530 10.1038/s41467-020-17029-3
51. Duan L Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing Front Genet 2021 12 673286 10.3389/fgene.2021.673286 34054927
Duan L, et al. Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing. Front Genet. 2021;12:673286.34054927 10.3389/fgene.2021.673286
52. Finsterer J Barth syndrome: mechanisms and management Appl Clin Genet 2019 12 95 106 10.2147/TACG.S171481 31239752
Finsterer J. Barth syndrome: mechanisms and management. Appl Clin Genet. 2019;12:95–106.31239752 10.2147/TACG.S171481
53 Pang J Barth Syndrome Cardiomyopathy: An Update Genes (Basel) 2022 13 4 656 10.3390/genes13040656 35456462
Pang J, et al. Barth Syndrome Cardiomyopathy: An Update. Genes (Basel). 2022;13(4):656.35456462 10.3390/genes13040656
54. Greenwell AA Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation Am J Physiol Heart Circ Physiol 2021 320 6 H2255 H2269 10.1152/ajpheart.00873.2020 33929899
Greenwell AA, et al. Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation. Am J Physiol Heart Circ Physiol. 2021;320(6):H2255–69.33929899 10.1152/ajpheart.00873.2020
55. Thompson R Current and future treatment approaches for Barth syndrome J Inherit Metab Dis 2022 45 1 17 28 10.1002/jimd.12453 34713454
Thompson R, et al. Current and future treatment approaches for Barth syndrome. J Inherit Metab Dis. 2022;45(1):17–28.34713454 10.1002/jimd.12453
56. Wang S AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine Knockout Model of Barth Syndrome Circ Res 2020 126 8 1024 1039 10.1161/CIRCRESAHA.119.315956 32146862
Wang S, et al. AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine Knockout Model of Barth Syndrome. Circ Res. 2020;126(8):1024–39.32146862 10.1161/CIRCRESAHA.119.315956
57. D’Souza RS Danon disease: clinical features, evaluation, and management Circ Heart Fail 2014 7 5 843 9 10.1161/CIRCHEARTFAILURE.114.001105 25228319
D’Souza RS, et al. Danon disease: clinical features, evaluation, and management. Circ Heart Fail. 2014;7(5):843–9.25228319 10.1161/CIRCHEARTFAILURE.114.001105
58. Boucek D Jirikowic J Taylor M Natural history of Danon disease Genet Med 2011 13 6 563 568 10.1097/GIM.0b013e31820ad795 21415759
Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med. 2011;13(6):563–8.21415759 10.1097/GIM.0b013e31820ad795
59. Taylor MRG Danon disease presenting with dilated cardiomyopathy and a complex phenotype J Hum Genet 2007 52 10 830 835 10.1007/s10038-007-0184-8 17899313
Taylor MRG, et al. Danon disease presenting with dilated cardiomyopathy and a complex phenotype. J Hum Genet. 2007;52(10):830–5.17899313 10.1007/s10038-007-0184-8
60. Yang Z Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children Circulation 2005 112 11 1612 1617 10.1161/CIRCULATIONAHA.105.546481 16144992
Yang Z, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation. 2005;112(11):1612–7.16144992 10.1161/CIRCULATIONAHA.105.546481
61. Charron P Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey Heart 2004 90 8 842 846 10.1136/hrt.2003.029504 15253947
Charron P, et al. Danon’s disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart. 2004;90(8):842–6.15253947 10.1136/hrt.2003.029504
62. Manso AM, et al. Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease. Sci Transl Med. 2020;12(535):eaax1744. 10.1126/scitranslmed.aax1744.
63. McNally EM Barefield DY Puckelwartz MJ The genetic landscape of cardiomyopathy and its role in heart failure Cell Metab 2015 21 2 174 182 10.1016/j.cmet.2015.01.013 25651172
McNally EM, Barefield DY, Puckelwartz MJ. The genetic landscape of cardiomyopathy and its role in heart failure. Cell Metab. 2015;21(2):174–82.25651172 10.1016/j.cmet.2015.01.013
64. Keyt LK Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics Front Cardiovasc Med 2022 9 972301 10.3389/fcvm.2022.972301 36158814
Keyt LK, et al. Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics. Front Cardiovasc Med. 2022;9:972301.36158814 10.3389/fcvm.2022.972301
65. Chai AC Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice Nat Med 2023 29 2 401 411 10.1038/s41591-022-02176-5 36797478
Chai AC, et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat Med. 2023;29(2):401–11.36797478 10.1038/s41591-022-02176-5
66. Reichart D Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice Nat Med 2023 29 2 412 421 10.1038/s41591-022-02190-7 36797483
Reichart D, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med. 2023;29(2):412–21.36797483 10.1038/s41591-022-02190-7
67. Mearini G Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice Nat Commun 2014 5 5515 10.1038/ncomms6515 25463264
Mearini G, et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nat Commun. 2014;5:5515.25463264 10.1038/ncomms6515
68. Dominguez F Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations J Am Coll Cardiol 2018 72 20 2471 2481 10.1016/j.jacc.2018.08.2181 30442290
Dominguez F, et al. Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations. J Am Coll Cardiol. 2018;72(20):2471–81.30442290 10.1016/j.jacc.2018.08.2181
69. Knezevic T BAG3: a new player in the heart failure paradigm Heart Fail Rev 2015 20 4 423 434 10.1007/s10741-015-9487-6 25925243
Knezevic T, et al. BAG3: a new player in the heart failure paradigm. Heart Fail Rev. 2015;20(4):423–34.25925243 10.1007/s10741-015-9487-6
70. Martin TG Cardiomyocyte contractile impairment in heart failure results from reduced BAG3-mediated sarcomeric protein turnover Nat Commun 2021 12 1 2942 10.1038/s41467-021-23272-z 34011988
Martin TG, et al. Cardiomyocyte contractile impairment in heart failure results from reduced BAG3-mediated sarcomeric protein turnover. Nat Commun. 2021;12(1):2942.34011988 10.1038/s41467-021-23272-z
71. Qu HQ Feldman AM Hakonarson H Genetics of BAG3: A Paradigm for Developing Precision Therapies for Dilated Cardiomyopathies J Am Heart Assoc 2022 11 23 e027373 10.1161/JAHA.122.027373 36382946
Qu HQ, Feldman AM, Hakonarson H. Genetics of BAG3: A Paradigm for Developing Precision Therapies for Dilated Cardiomyopathies. J Am Heart Assoc. 2022;11(23):e027373.36382946 10.1161/JAHA.122.027373
72. Myers VD Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals JAMA Cardiol 2018 3 10 929 938 10.1001/jamacardio.2018.2541 30140897
Myers VD, et al. Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals. JAMA Cardiol. 2018;3(10):929–38.30140897 10.1001/jamacardio.2018.2541
73. Knezevic T Adeno-associated Virus Serotype 9 - Driven Expression of BAG3 Improves Left Ventricular Function in Murine Hearts with Left Ventricular Dysfunction Secondary to a Myocardial Infarction JACC Basic Transl Sci 2016 1 7 647 656 10.1016/j.jacbts.2016.08.008 28164169
Knezevic T, et al. Adeno-associated Virus Serotype 9 - Driven Expression of BAG3 Improves Left Ventricular Function in Murine Hearts with Left Ventricular Dysfunction Secondary to a Myocardial Infarction. JACC Basic Transl Sci. 2016;1(7):647–56.28164169 10.1016/j.jacbts.2016.08.008
74. Myers VD Cardiac Transduction in Mini-Pigs After Low-Dose Retrograde Coronary Sinus Infusion of AAV9-BAG3: A Pilot Study JACC Basic Transl Sci 2022 7 9 951 953 10.1016/j.jacbts.2022.04.002 36317135
Myers VD, et al. Cardiac Transduction in Mini-Pigs After Low-Dose Retrograde Coronary Sinus Infusion of AAV9-BAG3: A Pilot Study. JACC Basic Transl Sci. 2022;7(9):951–3.36317135 10.1016/j.jacbts.2022.04.002
75. Duan D Duchenne muscular dystrophy Nat Rev Dis Primers 2021 7 1 13 10.1038/s41572-021-00248-3 33602943
Duan D, et al. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.33602943 10.1038/s41572-021-00248-3
76. Venugopal V, Pavlakis S. Duchenne muscular dystrophy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
77. Elangkovan N Dickson G Gene Therapy for Duchenne Muscular Dystrophy J Neuromuscul Dis 2021 8 s2 S303 S316 10.3233/JND-210678 34511510
Elangkovan N, Dickson G. Gene Therapy for Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2021;8(s2):S303–16.34511510 10.3233/JND-210678
78. Hoy SM Delandistrogene Moxeparvovec: First Approval Drugs 2023 83 14 1323 1329 10.1007/s40265-023-01929-x 37566211
Hoy SM. Delandistrogene Moxeparvovec: First Approval. Drugs. 2023;83(14):1323–9.37566211 10.1007/s40265-023-01929-x
79. Mullard A FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections Nat Rev Drug Discov 2023 22 8 610 10.1038/d41573-023-00103-y 37353665
Mullard A. FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections. Nat Rev Drug Discov. 2023;22(8):610.37353665 10.1038/d41573-023-00103-y
80. Chai AC Single-swap editing for the correction of common Duchenne muscular dystrophy mutations Mol Ther Nucleic Acids 2023 32 522 535 10.1016/j.omtn.2023.04.009 37215149
Chai AC, et al. Single-swap editing for the correction of common Duchenne muscular dystrophy mutations. Mol Ther Nucleic Acids. 2023;32:522–35.37215149 10.1016/j.omtn.2023.04.009
81. Chemello F, et al. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci Adv. 2021;7(18):eabg4910. 10.1126/sciadv.abg4910.
82. Happi Mbakam C, et al. Prime editing permits the introduction of specific mutations in the gene responsible for Duchenne muscular dystrophy. Int J Mol Sci. 2022;23(11):6160. 10.3390/ijms23116160.
83. Johnston JR, McNally EM. Genetic correction strategies for Duchenne muscular dystrophy and their impact on the heart. Prog Pediatr Cardiol. 2021;63:101460. 10.1016/j.ppedcard.2021.101460.
84. Bokhari SRA, Zulfiqar H, Hariz A. Fabry disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
85. Monda E Cardiovascular Involvement in Fabry's Disease: New Advances in Diagnostic Strategies, Outcome Prediction and Management Card Fail Rev 2023 9 e12 10.15420/cfr.2023.06 37602190
Monda E, et al. Cardiovascular Involvement in Fabry’s Disease: New Advances in Diagnostic Strategies, Outcome Prediction and Management. Card Fail Rev. 2023;9:e12.37602190 10.15420/cfr.2023.06
86. Pieroni M Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week J Am Coll Cardiol 2021 77 7 922 936 10.1016/j.jacc.2020.12.024 33602475
Pieroni M, et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(7):922–36.33602475 10.1016/j.jacc.2020.12.024
87. Deng M Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease Orphanet J Rare Dis 2023 18 1 275 10.1186/s13023-023-02894-0 37670350
Deng M, et al. Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease. Orphanet J Rare Dis. 2023;18(1):275.37670350 10.1186/s13023-023-02894-0
88. Jain A, Zahra F. Transthyretin amyloid cardiomyopathy (ATTR-CM). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
89. Kittleson MM Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association Circulation 2020 142 1 e7 e22 10.1161/CIR.0000000000000792 32476490
Kittleson MM, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7–22.32476490 10.1161/CIR.0000000000000792
90. Aimo A RNA-targeting and gene editing therapies for transthyretin amyloidosis Nat Rev Cardiol 2022 19 10 655 667 10.1038/s41569-022-00683-z 35322226
Aimo A, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol. 2022;19(10):655–67.35322226 10.1038/s41569-022-00683-z
91. Finn JD A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing Cell Rep 2018 22 9 2227 2235 10.1016/j.celrep.2018.02.014 29490262
Finn JD, et al. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. Cell Rep. 2018;22(9):2227–35.29490262 10.1016/j.celrep.2018.02.014
92. Gillmore JD CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis N Engl J Med 2021 385 6 493 502 10.1056/NEJMoa2107454 34215024
Gillmore JD, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021;385(6):493–502.34215024 10.1056/NEJMoa2107454
93 Bouchard C Tremblay JP Limb-Girdle Muscular Dystrophies Classification and Therapies J Clin Med 2023 12 14 4769 10.3390/jcm12144769 37510884
Bouchard C, Tremblay JP. Limb-Girdle Muscular Dystrophies Classification and Therapies. J Clin Med. 2023;12(14):4769.37510884 10.3390/jcm12144769
94. Cox GF Kunkel LM Dystrophies and heart disease Curr Opin Cardiol 1997 12 3 329 343 10.1097/00001573-199705000-00015 9243091
Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol. 1997;12(3):329–43.9243091 10.1097/00001573-199705000-00015
95. Silvestri NJ Cardiac involvement in the muscular dystrophies Muscle Nerve 2018 57 5 707 715 10.1002/mus.26014 29130502
Silvestri NJ, et al. Cardiac involvement in the muscular dystrophies. Muscle Nerve. 2018;57(5):707–15.29130502 10.1002/mus.26014
96. Semplicini C Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E Neurology 2015 84 17 1772 1781 10.1212/WNL.0000000000001519 25862795
Semplicini C, et al. Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology. 2015;84(17):1772–81.25862795 10.1212/WNL.0000000000001519
97. Hermann H Wuebbles RD Burkin DJ A gene therapy approach for the treatment of limb-girdle muscular dystrophy 2C/R5 Mol Ther Methods Clin Dev 2023 29 160 161 10.1016/j.omtm.2023.03.004 37063481
Hermann H, Wuebbles RD, Burkin DJ. A gene therapy approach for the treatment of limb-girdle muscular dystrophy 2C/R5. Mol Ther Methods Clin Dev. 2023;29:160–1.37063481 10.1016/j.omtm.2023.03.004
98. Seo YE Systemic gamma-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model Mol Ther Methods Clin Dev 2023 28 284 299 10.1016/j.omtm.2023.01.004 36816759
Seo YE, et al. Systemic gamma-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model. Mol Ther Methods Clin Dev. 2023;28:284–99.36816759 10.1016/j.omtm.2023.01.004
99. Sakuru R. Bollu PC. Hurler syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
100. van den Broek BTA Hurdles in treating Hurler disease: potential routes to achieve a "real" cure Blood Adv 2020 4 12 2837 2849 10.1182/bloodadvances.2020001708 32574368
van den Broek BTA, et al. Hurdles in treating Hurler disease: potential routes to achieve a “real” cure. Blood Adv. 2020;4(12):2837–49.32574368 10.1182/bloodadvances.2020001708
101. Wood SR Bigger BW Delivering gene therapy for mucopolysaccharide diseases Front Mol Biosci 2022 9 965089 10.3389/fmolb.2022.965089 36172050
Wood SR, Bigger BW. Delivering gene therapy for mucopolysaccharide diseases. Front Mol Biosci. 2022;9:965089.36172050 10.3389/fmolb.2022.965089
102. Bose SK In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease Nat Commun 2021 12 1 4291 10.1038/s41467-021-24443-8 34257302
Bose SK, et al. In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease. Nat Commun. 2021;12(1):4291.34257302 10.1038/s41467-021-24443-8
103. Salik I, Rawla P. Marfan syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
104. Kallenbach K, et al. Translational medicine: towards gene therapy of Marfan Syndrome. J Clin Med. 2022;11(14):3934. 10.3390/jcm11143934.
105. Zeng Y Correction of the Marfan Syndrome Pathogenic FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos Mol Ther 2018 26 11 2631 2637 10.1016/j.ymthe.2018.08.007 30166242
Zeng Y, et al. Correction of the Marfan Syndrome Pathogenic FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos. Mol Ther. 2018;26(11):2631–7.30166242 10.1016/j.ymthe.2018.08.007
106. Sickles CK, Gross GP. Progeria. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
107. Koblan LW In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice Nature 2021 589 7843 608 614 10.1038/s41586-020-03086-7 33408413
Koblan LW, et al. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature. 2021;589(7843):608–14.33408413 10.1038/s41586-020-03086-7
108. Williams CT, De Jesus O. Friedreich Ataxia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
109 Lynch DR Farmer G Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions Neuronal Signal 2021 5 2 NS20200093 10.1042/NS20200093 34046211
Lynch DR, Farmer G. Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions. Neuronal Signal. 2021;5(2):NS20200093.34046211 10.1042/NS20200093
110. Perdomini M Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia Nat Med 2014 20 5 542 547 10.1038/nm.3510 24705334
Perdomini M, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich’s ataxia. Nat Med. 2014;20(5):542–7.24705334 10.1038/nm.3510
111. Salami CO Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich's Ataxia Corrected by AAV-mediated Gene Therapy Hum Gene Ther 2020 31 15–16 819 827 10.1089/hum.2019.363 32646255
Salami CO, et al. Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich’s Ataxia Corrected by AAV-mediated Gene Therapy. Hum Gene Ther. 2020;31(15–16):819–27.32646255 10.1089/hum.2019.363
112. Ocana-Santero G Diaz-Nido J Herranz-Martin S Future Prospects of Gene Therapy for Friedreich's Ataxia Int J Mol Sci 2021 22 4 1815 10.3390/ijms22041815 33670433
Ocana-Santero G, Diaz-Nido J, Herranz-Martin S. Future Prospects of Gene Therapy for Friedreich’s Ataxia. Int J Mol Sci. 2021;22(4):1815.33670433 10.3390/ijms22041815
113. Rajkumar V, Dumpa V. Lysosomal storage disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
114. Stevens D Milani-Nejad S Mozaffar T Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview Curr Treat Options Neurol 2022 24 11 573 588 10.1007/s11940-022-00736-1 36969713
Stevens D, Milani-Nejad S, Mozaffar T. Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview. Curr Treat Options Neurol. 2022;24(11):573–88.36969713 10.1007/s11940-022-00736-1
115. Eggers M Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity EMBO Mol Med 2022 14 1 e13968 10.15252/emmm.202113968 34850579
Eggers M, et al. Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity. EMBO Mol Med. 2022;14(1):e13968.34850579 10.15252/emmm.202113968
116. Smith EC Phase I study of liver depot gene therapy in late-onset Pompe disease Mol Ther 2023 31 7 1994 2004 10.1016/j.ymthe.2023.02.014 36805083
Smith EC, et al. Phase I study of liver depot gene therapy in late-onset Pompe disease. Mol Ther. 2023;31(7):1994–2004.36805083 10.1016/j.ymthe.2023.02.014
117. Vora N, et al. Gene therapy for heart failure: a novel treatment for the age old disease. Dis Mon. 2023;70(2):101636. 10.1016/j.disamonth.2023.101636.
118. Argiro A, Ding J, Adler E. Gene therapy for heart failure and cardiomyopathies. Rev Esp Cardiol (Engl Ed). 2023;76(12):1042–1054
119. Lek A Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy N Engl J Med 2023 389 13 1203 1210 10.1056/NEJMoa2307798 37754285
Lek A, et al. Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy. N Engl J Med. 2023;389(13):1203–10.37754285 10.1056/NEJMoa2307798
